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We report that homeodomain-only protein (HOP) is expressed in the suprabasal layer of normal upper aerodigestive tract
epithelium and expression strongly decreases in hypopharyngeal carcinoma. Interestingly, HOP has very recently been shown to be a
tumour suppressor involved in differentiation, suggesting that HOP may have a similar role in head and neck squamous cell carcinoma
(HNSSC).
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Head and neck squamous cell carcinoma (HNSCC) occurs through
malignant conversion of basal layer epithelial cells of the upper
aerodigestive tract (pharynx, hypopharynx and larynx) and the
oral cavity. HNSSC is the fifth most common cancer worldwide
(Sankaranarayanan et al, 1998) and the 5-year survival rate is only
18% for hypopharyngeal carcinoma (Dimery and Hong, 1993). We
have performed differential display (DD) (Lemaire et al, 2003) and
DNA microarray (Cromer et al, 2004) analysis of hypopharyngeal
tumours to search for new biomarkers and targets for drug design.
In this complementary study, we report that expression of
homeodomain-only protein (HOP) is strongly decreased in
tumours. Interestingly, in a series of recent independent reports,
this protein under different names (mOB1/HOP/LAGY/NECC1/
SMAP31) has been shown to be involved in development (Adu
et al, 2002; Chen et al, 2002; Shin et al, 2002; Asanoma et al, 2003;
Chen et al, 2003) and has been shown to be a potent tumour
suppressor (Asanoma et al, 2003). We show here that HOP is
expressed at a precise stage of epidermoid cell differentiation and
its expression is lost in HNSSC, suggesting that HOP may be a
general tumour suppressor gene involved in keratinocyte differ-
entiation.
MATERIALS AND METHODS
Tumour samples, Northerns, Virtual Northerns and real-time
quantitative PCR (RT–QPCR) were as described previously
(Lemaire et al, 2003). Virtual signifies the use in the Northern
blots of SMART cDNA synthesised by SMART (Clontech, http://
www.bdbiosciences.com/clontech/). The primer sequences were
HOP, 50-TCAACAAGGTCGACAAGCAC-30 and 50- TCTGTGACG-
GATCTGCACTC-30; the ubiquitous gene RPLPO, 50-
GAAGGCTGTGGTGCTGATGG-30 and 50- CCGGATATGAGGCAG-
CAGTT -30. For each PCR, the unknown sample expression level
was estimated relative to standard curves using a pool of normal
samples. PCR reactions were run at least twice for each sample and
results normalised using RPLP0 as an internal control. In situ
hybridisation (ISH) was performed by a standard technique
(Strahle et al, 1994; Cau et al, 1997). Nonradioactive digoxigen-
ine-labelled RNA probes were synthesised from 15mg of linearised
F1.4-pGEMT-Easy (antisense: Aat2 and SP6 RNA polymerase;
sense: Spe1 and T7 polymerase). F1.4-pGEMT-Easy: pGEM-T Easy
with a 572bp insert corresponding to SMAP31 (now HOP
transcript variant 1, accession number BC014225, nt 675–1246).
RESULTS
We isolated a differentially expressed sequence (F1. 4) in a DD
analysis of RNA from HNSCC and matching normal tissue. The
sequence corresponded to SMAP31/LAGY, which at that time was
annotated in the NCBI database as a clone underexpressed in
choriocarcinoma vs normal placenta villi (SMAP31) and lung
cancer vs normal lung (LAGY). More recently, it has been called
HOP (Chen et al, 2002; Shin et al, 2002) since it is a homeodomain-
only protein. Homeodomain-only protein was not detected in our
previous study (Lemaire et al, 2003), apparently because it is not
efficiently labelled with the primer mixtures that we used to make
focused probes for Reverse Northern analysis. However, in further
studies using Virtual Northerns (Northerns with SMART amplified
cDNAs), we found a striking decrease in expression in tumours in
nine matched tumour-normal pairs (Figure 1A). The major
transcript migrates around 1000bp, which corresponds to the
sizes reported for HOP (1200bp, (Chen et al, 2002; Shin et al,
2002)), LAGY (HOP/LAGY transcript variants: 1013bp,
NM_139212; 989bp, NM_139211, 1265bp, NM_032495 (Chen
et al, 2003)), and NECC1/SMAP31-22, SMAP31-R and SMAP31-
12 (980bp, AB059409, 989bp, AB059410 and 1097bp, AB059408,
respectively, (Asanoma et al, 2003)]).
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(Figure 1B) and slot (data not shown) blotting. As expected, the
predominant band on Northerns migrates around 1000bp
(compared to the ribosomal RNA markers, Figure 1B). HOP
expression was found to be decreased in 18 out of 19 tumours
compared to normal samples. Expression of HOP was also
decreased in involved lymph nodes (L; Figure 1B, patients 11, 13,
14). The expression levels of HOP were assessed by RT-QPCR in a
panel of 33 hypopharyngeal carcinomas, for which there were 23
matched normal tissues (Figure 2). HOP was expressed at high
levels in normal samples (21 out of 23) and strikingly decreased in
all tumour samples (average fold change¼27). In situ hybridisa-
tion (ISH) of frozen sections was used to localise HOP mRNA
expression (Figure 3). HOP expression was detected in the
suprabasal layer of the epithelium of normal tissue (uvula) (3A,
antisense; 3B, haematoxylin/eosin). There was no significant signal
with the sense probe and normal tissue, or with the antisense
probe and several tumour samples (data not shown). The
expression pattern is compatible with a role for HOP in epithelial
differentiation and suggested that HOP expression might be
associated with the degree of differentiation of the tumours.
Homeodomain-only protein expression, measured by RT-QPCR,
indicates that there is no statistically significant difference
according to the histopathological differentiation status of HNSCC
tumours (P¼0.16; Figure 2).
DISCUSSION
We have shown that HOP expression is strikingly decreased in
hypopharyngeal HNSSC, in 44 out of 46 patients analysed. We also
observed decreased HOP expression in tumours by microarray
analysis (Cromer et al, 2004). HOP was found to be expressed in
the suprabasal layer of the epithelium, pointing to a role in
keratinocyte differentiation.
There is a striking recent convergence of results from several
laboratories that indicate that HOP is an important new tumour
suppressor. Several studies showed that HOP (mOB1) is expressed
during mouse development (Adu et al, 2002) and is involved in
cardiac development (Chen et al, 2002; Shin et al, 2002). More
recently, HOP was shown to be a choriocarcinoma suppressor gene
involved in cytotrophoblast differentiation (Asanoma et al, 2003),
and to be underexpressed in primary lung tumours compared with
normal lung (Chen et al, 2003). Homeodomain-only protein is
located in a chromosomal region (4q11–q12) that is frequently
deleted in solid tumours, including lung tumours, hepatocellular
carcinoma and bladder cancer (Petersen et al, 1997; Koo et al,
1999; Sakakura et al, 1999; Wong et al, 1999). Our study provides
evidence for a role of HOP in HNSCC.
HOP consists of 73 amino acids with an unusual 60 amino-acid
homeodomain, and is the smallest homeodomain protein to date.
Homeodomain proteins are important for embryogenesis and
development (reviewed in (Chi and Epstein, 2002; Duboule, 1994)).
HOP does not possess conserved homeodomain residues needed
for DNA binding, but modulates cardiac genes expression by direct
interaction with SRF and inhibition of SRF binding to DNA (Chen
et al, 2002; Shin et al, 2002).
HOP is widely expressed in mouse and human tissues,
suggesting that it may have an important role in many cell types.
Using adult human tissue dot blots (Clontech ref PT3307-1), we
found expression in oesophagus, lung, placenta, thyroid gland,
foetal lung and brain (in decreasing order, data not shown). The
cellular localisation of HOP is predicted to be mainly nuclear. We
found, by immunocytochemistry with our specific antibodies and
HaCat spontaneously immortalized keratinocytes, that endogenous
HOP is nuclear (data not shown), in agreement with others (Chen
et al, 2002; Shin et al, 2002).
HOP expression has been detected in primary cultures of
normal lung but not in lung tumour-derived cell lines (Chen et al,
2003). Similarly, we detected, by semiquantitative RT–PCR,
expression in primary keratinocytes and HaCat cells, but not in
a panel of 15 HNSCC-derived cell lines (data not shown).
Reintroduction of HOP in choriocarcinoma cell lines inhibits cell
proliferation and tumour formation in nude mice (Asanoma et al,
2003). We report that HOP expression is decreased in HNSCC
tumours compared to their normal matched samples, consistent
with studies in other cancer types (Asanoma et al, 2003; Chen et al,
2003). The reduction of HOP/LAGY expression in lung squamous
cell carcinoma is correlated with increasing TNM staging. A
complete loss of expression of HOP in two poorly differentiated
lung tumour samples has also been reported (Chen et al, 2003). In
our study, there is no statistically significant association with
tumour differentiation, suggesting that loss of HOP expression is
important in all tumours despite the degree of differentiation. We
have shown that HOP is expressed in the suprabasal layer of the
upper aerodigestive tract epithelium, suggesting that it is involved
in keratinocyte differentiation. HOP is potentially responsible
for the balance between proliferation and differentiation of
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Figure 1 Analysis of HOP RNA expression by Virtual Northern blots (A) and Northern blots (B). Bars indicate tumour (T) and normal (N) samples from
the same patients. Comparisons should be made between matched samples. RPLP0 is the loading control.
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expression Of HOP in choriocarcinoma cell lines induces the
expression of CSH1, a marker of differentiated syncytiotropho-
blasts (Asanoma et al, 2003). Taken together, the results in HNSCC
and in other cancer types indicate that HOP could be an important
tumour suppressor gene in a wide range of solid tumours.
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Patients: 
Normal samples Tumour samples
High diff  Low diff Moderate diff
P < 0.001
P = 0.16
AB
C
n = 9
38 ± 24
n = 9
29 ± 31
n = 11
28 ± 33
n = 33
30 ± 28
n = 23
390 ± 198
n = 4
16 ± 11
Undiff
Figure 2 Real-time quantitative RT–PCR. (A, B) Traces and standard curves of HOP (A) and RPLP0 (B) analysis for tumour samples (full line) and
normal samples (long dotted line). Control without cDNA (short dotted line). (C). HOP expression was analysed in 33 hypopharyngeal tumours and 23
matched normal samples by RT–QPCR. HOP expression values were calculated in relative units adjusted to the RPLP0 internal controls. Statistical analysis
between tumour and normal samples, and between tumours according to their histopathological differentiation status, were carried out by ANOVA
statistical tests.
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